Testosterone is named as an intervention in 7 current clinical trials in our Denmark, UK, Netherlands, Belgium, Switzerland and Canada registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Transdermal Delivery Solutions Corp (1). The most-studied condition is Klinefelter Syndrome. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life
NCT07143279 · ClinicalTrials.gov ↗ · Hypotestosteronism, Palliative Care
|
Phase EARLY_PHASE1 | Recruiting | Jules Bordet Institute | Belgium |
|
Klinefelter Syndrome and Testosterone Treatment in Puberty
NCT06294990 · ClinicalTrials.gov ↗ · Klinefelter Syndrome
|
Phase 4 | Recruiting | Lise Aksglæde | Denmark |
|
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
NCT04833426 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Hypogonadism, Testosterone Deficiency
|
Phase 3 | Recruiting | Canisius-Wilhelmina Hospital | Netherlands |
|
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
NCT05586802 · ClinicalTrials.gov ↗ · Klinefelter Syndrome
|
Phase 3 | Recruiting | Georgios Papadakis | Switzerland |
|
COMPASS - COpenhagen MenoPAuSe Study
NCT07254429 · ClinicalTrials.gov ↗ · Menopausal Osteoporosis, Bone Markers
|
Phase 2 | Recruiting | Martin Blomberg Jensen | Denmark |
|
A Dose Ranging Study to Examine TDS-Testosterone 5%
NCT01894308 · ClinicalTrials.gov ↗ · Hypogonadotropism
|
Phase 2 | Not yet open | Transdermal Delivery Solutions Corp | UK |
|
The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans
NCT07212712 · ClinicalTrials.gov ↗ · Cerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences
|
Not applicable | Not yet open | University of British Columbia | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Testosterone. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial
2024-518120-68-01 · CTIS ↗ · Mental Disorders
|
Phase 2 | Authorised | Vaestra Goetalandsregionen | Sweden |
|
Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.
2024-510596-37-01 · CTIS ↗ · Female Urogenital Diseases and Pregnancy Complications
|
Phase 3 | Authorised | Instituto Bernabeu S.L | Spain |
|
Testosterone supplementation in patients in best supportive care: impact on quality of life.
2025-522023-10-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Ongoing | Institut Jules Bordet | Belgium |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
7 single-substance products containing Testosterone on the HPRA medicines list.
No entry for Testosterone in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Klinefelter Syndrome | 2 |
| Hypogonadotropism | 1 |
| Prostatic Neoplasms | 1 |
| Hypogonadism | 1 |
| Testosterone Deficiency | 1 |
| Hypotestosteronism | 1 |
| Palliative Care | 1 |
| Menopausal Osteoporosis | 1 |
| Bone Markers | 1 |
| Cerebral Blood Flow | 1 |
| Cerebral Blood Flow Regulation | 1 |
| Sex Differences | 1 |
| Exercise | 1 |
| Lead sponsor | Trials |
|---|---|
| Transdermal Delivery Solutions Corp | 1 |
| Canisius-Wilhelmina Hospital | 1 |
| Jules Bordet Institute | 1 |
| Lise Aksglæde | 1 |
| Martin Blomberg Jensen | 1 |
| Georgios Papadakis | 1 |
| University of British Columbia | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Denmark | 2 | 2 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Belgium | 1 | 1 |
| Clinical trials in Switzerland | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
7 current trials in our Denmark, UK, Netherlands, Belgium, Switzerland and Canada registers name Testosterone (also registered as Sustanon 250) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 7 trials are recruiting: 2 with sites in Denmark, 1 with sites in Netherlands, 1 with sites in Belgium and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Transdermal Delivery Solutions Corp (1), Canisius-Wilhelmina Hospital (1), Jules Bordet Institute (1) and Lise Aksglæde (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 7 single-substance products containing Testosterone, for example Testarzon 20 mg/g Transdermal gel (The Simple Pharma Company Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Testosterone has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Testosterone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Testosterone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Testosterone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.